PMID- 19530558
OWN - NLM
STAT- MEDLINE
DCOM- 20090716
LR  - 20171116
IS  - 0738-0658 (Print)
IS  - 0738-0658 (Linking)
VI  - 28
IP  - 2
DP  - 2009 Jun
TI  - Acquired acute myelogenous leukemia after therapy for acute promyelocytic 
      leukemia with t(15;17): a case report and review of the literature.
PG  - 146-50
AB  - Therapy-related myelodysplastic syndrome (t-MDS) and therapy-related acute 
      myelogenous leukemia (t-AML) in patients with acute promyelocytic leukemia (APL) 
      are rare events. The cumulative exposure to chemotherapy with alkylating agents 
      and topoisomerase II inhibitors is associated with t-AML that may develop any 
      time after the completion of the treatment. We report the case of an acquired AML 
      who previously received therapy for APL, after two years of being diagnosed. The 
      diagnosis was established by morphologic findings, membrane markers, cytogenetic 
      studies, and fluorescence in situ hybridization (FISH). To our knowledge this is 
      the first documented case in Puerto Rico of a patient with APL that developed a 
      t-AML without the characteristic chromosomal and morphologic findings of APL.
FAU - Betancourt-Garcia, Rafael D
AU  - Betancourt-Garcia RD
AD  - Hematology-Oncology Section, University District Hospital, UPR School of 
      Medicine, San Juan, Puerto Rico.
FAU - Castro, Justiniano
AU  - Castro J
FAU - Fernandez, Adry C
AU  - Fernandez AC
FAU - Lopez-Enriquez, Alberto
AU  - Lopez-Enriquez A
FAU - Fradera, Jean
AU  - Fradera J
FAU - Pacheco, Eileen
AU  - Pacheco E
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
PL  - Puerto Rico
TA  - P R Health Sci J
JT  - Puerto Rico health sciences journal
JID - 8303541
RN  - 0 (Antineoplastic Agents, Alkylating)
RN  - 04079A1RDZ (Cytarabine)
RN  - 5688UTC01R (Tretinoin)
RN  - BZ114NVM5P (Mitoxantrone)
RN  - E7WED276I5 (Mercaptopurine)
RN  - YL5FZ2Y5U1 (Methotrexate)
RN  - ZS7284E0ZP (Daunorubicin)
SB  - IM
MH  - Adult
MH  - Antineoplastic Agents, Alkylating/administration & dosage/adverse effects
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use
MH  - Chromosomes, Human, Pair 15/ultrastructure
MH  - Chromosomes, Human, Pair 17/ultrastructure
MH  - Chromosomes, Human, Pair 21/ultrastructure
MH  - Chromosomes, Human, Pair 3/ultrastructure
MH  - Chromosomes, Human, Pair 7
MH  - Cytarabine/administration & dosage
MH  - Daunorubicin/administration & dosage/adverse effects
MH  - Drug Synergism
MH  - Fatal Outcome
MH  - Humans
MH  - Leukemia, Myeloid, Acute/drug therapy/*etiology/genetics
MH  - Leukemia, Promyelocytic, Acute/*drug therapy/genetics
MH  - Male
MH  - Mercaptopurine/administration & dosage
MH  - Methotrexate/administration & dosage/adverse effects
MH  - Mitoxantrone/administration & dosage/adverse effects
MH  - Monosomy
MH  - Neoplasms, Second Primary/*etiology/genetics
MH  - *Translocation, Genetic
MH  - Tretinoin/administration & dosage
RF  - 26
EDAT- 2009/06/18 09:00
MHDA- 2009/07/17 09:00
CRDT- 2009/06/18 09:00
PHST- 2009/06/18 09:00 [entrez]
PHST- 2009/06/18 09:00 [pubmed]
PHST- 2009/07/17 09:00 [medline]
PST - ppublish
SO  - P R Health Sci J. 2009 Jun;28(2):146-50.